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Original Article
Abstract
Purpose: To assess the dosimetry to organs at risk (OARs) in lithotomy position with a planned time-dose pattern obtained from
supine position. Methods: The sample consists of thirty patients with carcinoma of the uterine cervix, Stage II and III. Patients
often feel discomfort in supine position (S position) when compared to lithotomy position (M position) due to relaxation of pel-
vic floor muscles after the insertion of applicator (tandem and ovoids) or before delivery of the treatment. Each patient was
imaged with orthogonal X- ray radiographs simultaneously in two positions, i.e. S position and M position. Dwell time and
dwell position pattern obtained from the optimized plan in S position was used to generate plan in M position. Following dose
reference points (point A, pelvic wall points, bladder points, rectal, anorectum (AR point) and rectosigmoid (RS point) points)
were identified for analysis in S and M positions. The dosimetric data for reference points generated by the Brachyvision TPS
was analyzed. Results: Pelvic wall points registered lower doses in M position when compared to S position. Mean doses for
right pelvic wall point (RPW) and left pelvic wall point (LPW) were reduced by -10.02 % and -11.5% in M position, respec-
tively. International Commission on Radiation Units and Measurements (ICRU) bladder point also registered lower doses in M
position with a mean dose of -6.8%. Rectal point showed dose reduction by mean of -6.4%. AR and RS points showed an in-
creased dose in M position by a mean of 16.5% and 10%, respectively. Conclusion: Current dosimetry procedure serves as a
model with time-dose pattern planned for S position, but delivered in M position, without dose optimization. Prioritization of
comfort and position can be considered in conjunction with optimization of dose.
Keywords: Supine; Lithotomy; Time Dose Pattern; Bladder; Rectum
Introduction
Carcinoma of the uterine cervix is a radiosensitive tumour.
Radiotherapy is primary modality of treatment in locally
advanced uterine cervix cancers. Intracavitary brachythera-
py (ICBT) along with external beam radiotherapy (EBRT) are
essential components of cervical cancer management. ICBT
has a high therapeutic index by delivering high dose to the
tumour and lower doses to adjacent organs (without increase
in toxicity), resulting in increased local control and surviv-
al.1-4 Radiotherapy is a multi-stage, complex procedure re-
quires high level of accuracy at each stage to achieve maxi-
mum tumour control with minimum normal tissue compli-
cations.
High dose rate (HDR) brachytherapy is comparable to low
dose rate (LDR) brachytherapy in treatment of uterine cervix
cancers. The advantages of HDR over LDR brachytherapy
have been extensively reviewed.5-8 Since HDR brachythera-
py is fractionated, treatment planning and dose optimization
is recommended for each fraction for the following reasons.
First, the anatomy of the region (uterine cervix and upper
vagina) changes during the course of irradiation. Second,
geometry of the applicators changes as a consequence of the
differences in vaginal packing and anatomical position of the
patient. 9-15 As a result every parameter that influences the
treatment should be thoroughly studied.
Cancer uterine cervix patients often feel discomfort during
intracavitary brachytherapy application procedure and
treatment. Discomfort can be addressed with application
under short sedation in supine position (S position), which is
the usual anatomical position for treatment delivery. This
discomfort is reduced for some patients in lithotomy position
(M position) because of the relaxation of muscles of the pel-
vis. Adopting lithotomy position requires repetition of the
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entire procedure of imaging, image transfer, planning, plan
verification and data transfer to treatment console which is
time consuming. Instead, dose variation can be studied in
both positions with the same loading pattern. On similar
lines some studies attempted adopting standard treatment
plans with an aim to reduce turnaround time thus providing
comfort to the patient.16-17
The current study serves to evaluate a case scenario using
lithotomy position. An analysis of the risk involved, if any,
with respect to higher doses to organs at risk (OARs) can be
studied if patient comfort is prioritized. United States Nucle-
ar Regulatory Commission (USNRC) standards document 18
throws light on HDR brachytherapy issues such as wrong
site treated, wrong dose delivered etc. Present article adds to
the current literature in analysing situations where in do-
simetry is assessed with patients in M position with the
time-dose pattern obtained from S position.
Methods and Materials
The study sample consists of thirty patients with carcinoma
uterine cervix, Stage II and grade III with age ranging from
30 - 60 years. All patients were recruited with the approval
of hospital ethics committee. Standard Henschke applicator
set (Mick Radio-Nuclear Instruments, Inc., NY, and USA)
with different tandem lengths and ovoid diameters was used
depending on patients’ anatomy. Tandem length varies be-
tween 4 to 6 cm and ovoids diameter ranges from 2 to 3 cm.
Each patient was imaged simultaneously in two positions, i.e.
S Position and M Position, on Acuity physical simulator
(Varian, Palo Alto, CA, USA). Orthogonal digital X-ray im-
ages in anterior-posterior and lateral directions at gantry
angles 0˚ and 270˚respectively were obtained to confirm the
adequacy of position and orientation of the applicator set.
Images were transferred to the Brachyvision treatment plan-
ning system (TPS), version 7.3 (Varian Medical System, Palo
Alto, CA, USA) via ARIA network (Varian, Palo Alto, CA,
USA) for planning.
Prescription dose ranging from 600 cGy to 700 cGy were
optimized to Point A and to reference lines placed at 0.5 cm
apart from surface of ovoids. Dwell time and dwell position
pattern obtained from the optimized plan in S Position was
used to generate plan in M position. Neither of the plans was
executed on the patient because OAR violations were not
verified and used for analysis only. Following dose reference
points (point A, pelvic wall points, bladder points, rectal,
anorectum (AR point) and rectosigmoid (RS point) points)
were identified for analysis in S and M positions (Figure 1).
All the plans were generated for the first fraction of HDR
Brachytherapy to rule out the anatomical variation during
the course of treatment such as tumor regression, bladder
and rectal fillings.19 Doses were calculated by Brachyvision
treatment planning system using Task Group-43 (TG-43)
algorithm with a dose calculation gird size of 2 mm. Typical
dose distribution is shown in the Figure 2.
Point A, pelvic wall reference points and bladder points are
identified in accordance with International Commission on
Radiation Units and Measurements (ICRU) 38 recommenda-
tions.20 In addition to the ICRU bladder point, two more
points were digitized at superior and inferior surface of the
Foleys’ bulb (Figure 1). A dummy marker wire is placed in
the rectal tube to locate the modified rectal point. Rectal
point was identified at a point anterior to the rectal marker
wire in lateral view at the level of line joining the centres of
right and left femoral heads in anterior-posterior view. Two
additional rectal points are marked at 1 cm on either side of
the modified rectal point in cranio-caudal direction. AR
point was mimicked with a point located at 2 cm superior to
the point on the rectal marker wire at the inferior level of
pelvic girdle. RS point was identified at the anterior surface
of S1-S2 junction in lateral view and at the same level on the
midline in anterior-posterior view.
FIG. 1: Lateral X- ray radiographs inM and S positions.
FIG. 2: Typical Isodose distribution.
Pitch of the tandem applicator is obtained by measuring the
angle between the line passing from the tip of the tandem
through centre of the flange and a line parallel to the length
of the template field of size 10 cm × 10 cm used to scale the
radiograph, along the patient, on the lateral radiograph (Fig-
ure 3). The difference of the measured angles, (θ1 - θ2), in S
(θ1) and M (θ2) positions gives an estimate of the pitch due to
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change in anatomical position (Figure 3). Data normality was
assessed using the Klomogorov-Smirnov test and statistical
analysis was performed using the software SAS version 9.4
(SAS Institute., Inc., Cary, NC). P-values were calculated
with Student’s paired t test.
FIG.3: Pitch of the applicator with respect to external template field.
Results
The dosimetric data of dose reference points generated by
the Brachyvision TPS was analyzed. The relative variation of
doses in two anatomical positions is expressed as ratio of dose
difference between M and S positions to dose in S position. A
positive value indicates higher dose in M position and a neg-
ative value indicates a lower dose. Out of 30 patients, 23
patients received 7 Gy, 3 patients received 6.5 Gy, and 4
patients received 6 Gy, per fraction. Point A exhibited a little
dose difference in two positions with a range from -6.9% to
5.4% and a mean of 0.3%.
TABLE 1: The mean dose differences between TPS values in M and S
positions as percentage of values obtained with patient in S position.
Point/ OAR Mean dose difference p value
RPW -10.02 ˂0.001
LPW -11.5 ˂0.001
Bladder point -6.8 ˂0.001
Rectal point -6.4 0.007
AR point 16.5 ˂0.001
RS point 10.0 <0.001
Pelvic wall points registered lower doses in M position when
compared to S position. For the right pelvic wall point
(RPW), the mean dose was -10.02% with a range from 7.7%
to -28.2%. For the left pelvic wall point (LPW), the mean
dose was -11.5% with a range from 5.2% to -29.7%. ICRU
bladder point also registered lower doses in M position with
a range from 5.2% to -29.7% with a mean dose of -6.8%.
Rectal point showed reduction in dose by mean of -6.4%
with a range from -26.9% to 15.1%. Anorectal junction point
and Rectosigmoid point showed an increased dose in M posi-
tion by a mean of 16.5% with a range from -2.58% to 34.1%
and with a mean of 10% with a range from -19.4% to 32.5%,
respectively.
Discussions
The main aim of the study was to assess the change in do-
simetry due to change in patients’ anatomical position. In the
present study, 60 plans on thirty patients with two plans per
patient in S and M positions were created and analyzed. Dif-
ferent treatment positions are evaluated in both external
beam therapy 21-23 and brachytherapy 24-27 for treatment of
various sites. In case of brachytherapy there are studies on
the use of template based standard plans versus individual-
ized plans and pre-prepared treatment plans for curved
structures such as esophagus.28 There are few studies which
evaluated variability of position of ring and tandem applica-
tors 29-30 in ICBT in cancer cervix patients. Vaginal cuff irra-
diation is well studied with change in applicator angle 32 and
patients position.33 This study is one of the very few studies
done till date to evaluate dosimetric variations in different
anatomical positions in cervical cancer patients when treated
with tandem and ovoid applicator.
To characterize the applicator orientation changes additional
dose reference points are added for rectum and bladder
points and analyzed. Analysis of posterior reference points
shows increase of dose in craniocaudal direction from RS
point till inferior rectal point (RLI) (Figure 4). RS and AR
points receive lower doses compared to rectal points as they
are located at the extreme ends of the source arrangement.
From Figure 4 it can be inferred that the dose to posterior
points follows a similar trend for both positions. However,
higher doses are observed for rectal points in S position and
RS and AR points in M position. Among the anterior refer-
ence points, bladder superior point (BLS) shows a decrease in
dose in S position and bladder inferior point (BLI) dose is
higher in M position. Rearrangement in applicator-anatomy
was observed from S position to M position, as same dwell
time pattern is adopted for both positions. It was observed
that in M position posterior points registered relatively flat-
ter values as compare to S position. Figure 5 shows the mean
dose variations of anterior reference points. Dose decreased
to BLS point by a mean of -9.8% and an increase in dose to
BLI point by 2.9% was observed in M position. Tandem rota-
tion towards posterior structures in M position was observed
with tip of the tandem drifting away from BLS point result-
ing in higher dose to BLS point. The mean difference in rota-
tions was 100 between two positions and consequently the
mean dose to RS and AR points were increased in M posi-
tion. Previous studies measured translational shifts only in
anterior-posterior direction26 or in other applicator geometry
such as ring and tandem for one anatomical position i.e.,
supine only.30-31 Rotational shift associated with change in
applicator angle was reported by Hoskins et al.32 and is about
200. The higher degree of rotation reported in their study
may be due to single line source used for vaginal cuff
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brachytherapy. This is not the case with tandem and ovoid
pair applicators used for cancer of cervix and the rotation
reported in this case is not comparable to that for vault
brachytherapy.
FIG. 4: Mean dose variation of posterior points in S andM positions.
FIG. 5: Mean dose variation for bladder points in S andM positions.
The consequences of transposing dwell pattern to M position
are summarized. Dose to RS and AR points maximized in
most of the cases. Both these points recorded a maximum of
30%. Pelvic wall points, on the contrary, recorded a
minimum, close to 30%. Similarly, reduction in dose to BLS
point was compromised with a higher dose to BLI point.
However, the mean dose to the bladder and rectum points
was on the lower side which is a favourable result.
Conclusion
This study presents a case scenario, evaluating lithotomy
position for dosimetry of various OARs. We conclude that
reduction in dose to bladder and rectum is compromised
with elevated doses to rectosigmoid and anorectal points.
The current dosimetry procedure serves as a future model
and can be correlated with a patient treated with time-dose
pattern planned for S position, but delivered in M position,
without dose optimization. Prioritization of comfort and
position can be taken seriously but in conjunction with op-
timization of dose. Further studies in this respect with 3D
planning are needed to add to the literature.
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